U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C3H5N3O9
Molecular Weight 227.0867
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NITROGLYCERIN

SMILES

C(C(CON(=O)=O)ON(=O)=O)ON(=O)=O

InChI

InChIKey=SNIOPGDIGTZGOP-UHFFFAOYSA-N
InChI=1S/C3H5N3O9/c7-4(8)13-1-3(15-6(11)12)2-14-5(9)10/h3H,1-2H2

HIDE SMILES / InChI

Molecular Formula C3H5N3O9
Molecular Weight 227.0867
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/16103363 | https://www.ncbi.nlm.nih.gov/pubmed/22040938

Nitroglycerin was first invented in 1847 and has been used as an active ingredient in the manufacture of explosives, mostly dynamite. Nitroglycerin came into medical use in 1878 as as a potent vasodilator (dilation of the vascular system) to treat heart conditions, such as angina pectoris and chronic heart failure. Upon administration, nitroglycerin is converted to nitric oxide (NO) by mitochondrial aldehyde dehydrogenase. NO is a potent activator of guanylyl cyclase (GC) by heme-dependent mechanisms.

Originator

Curator's Comment:: Nitroglycerin was first synthesized by the Italian chemist Ascanio Sobrero in 1847, working under Théophile-Jules Pelouze at the University of Turin

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
NITROSTAT

Approved Use

Acute relief of angina pectoris secondary to CAD; acute prophylactic management in situations likely to provoke angina attacks; and long-term prophylactic management of angina pectoris.

Launch Date

9.4703039E11
Primary
NITROGLYCERIN

Approved Use

Management of patients with acute myocardial infarction (MI). Nitroglycerin is one of the principal initial therapies of MI.

Launch Date

3.71174408E11
Primary
NITROGLYCERIN

Approved Use

IV nitroglycerin is used to control BP in perioperative hypertension, especially hypertension associated with cardiovascular procedures; to control BP in patients with severe hypertension† or in hypertensive crises for the immediate reduction of BP in patients in whom such reduction is considered an emergency (hypertensive emergencies), especially those associated with coronary complications (e.g., coronary ischemia, acute coronary insufficiency, acute left ventricular failure, postoperative hypertension [especially following coronary bypass surgery]); and to produce controlled hypotension during surgical procedures.

Launch Date

3.71174408E11
Primary
NITROGLYCERIN

Approved Use

IV nitroglycerin has been used in the management of acutely decompensated (e.g., congestive) heart failure and other low cardiac-output states.

Launch Date

3.71174408E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.7 pg/mL
800 μg single, sublingual
dose: 800 μg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
NITROGLYCERIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
84 ng/mL
13 mg single, oral
dose: 13 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GLYCERYL 1,2-DINITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
12.3 pg × min/mL
800 μg single, sublingual
dose: 800 μg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
NITROGLYCERIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3380 ng × min/mL
13 mg single, oral
dose: 13 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GLYCERYL 1,2-DINITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
40 min
800 μg single, sublingual
dose: 800 μg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
NITROGLYCERIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
50 min
13 mg single, oral
dose: 13 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GLYCERYL 1,2-DINITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1 ug/kg/min multiple, intravenous (starting)
Dose: 1 ug/kg/min
Route: intravenous
Route: multiple
Dose: 1 ug/kg/min
Sources:
pregnant, 26 years
n = 16
Health Status: pregnant
Condition: Preterm labor
Age Group: 26 years
Sex: F
Population Size: 16
Sources:
Disc. AE: Hypotension...
AEs leading to
discontinuation/dose reduction:
Hypotension (4 patients)
Sources:
8 ug/kg/min multiple, intravenous
Dose: 8 ug/kg/min
Route: intravenous
Route: multiple
Dose: 8 ug/kg/min
Sources:
pregnant, 26 years
n = 1
Health Status: pregnant
Condition: Preterm labor
Age Group: 26 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea (severe, 1 patient)
Vomiting (severe, 1 patient)
Headache (severe, 1 patient)
Sources:
35 ug/kg/min single, intravenous
Dose: 35 ug/kg/min
Route: intravenous
Route: single
Dose: 35 ug/kg/min
Sources:
unhealthy, 50 years (range: 19 ± 74 years)
n = 105
Health Status: unhealthy
Age Group: 50 years (range: 19 ± 74 years)
Sex: M+F
Population Size: 105
Sources:
Disc. AE: Hemodynamic test abnormal...
AEs leading to
discontinuation/dose reduction:
Hemodynamic test abnormal (8 patients)
Sources:
0.6 mg/h 1 times / day multiple, transdermal
Highest studied dose
Dose: 0.6 mg/h, 1 times / day
Route: transdermal
Route: multiple
Dose: 0.6 mg/h, 1 times / day
Sources:
unhealthy, 51.4 ±4.3 years
n = 11
Health Status: unhealthy
Condition: menopausal hot flashes
Age Group: 51.4 ±4.3 years
Sex: F
Population Size: 11
Sources:
2 % 6 times / day multiple, topical
Dose: 2 %, 6 times / day
Route: topical
Route: multiple
Dose: 2 %, 6 times / day
Sources:
unhealthy, 57 - 71 years
n = 2
Health Status: unhealthy
Age Group: 57 - 71 years
Sex: M
Population Size: 2
Sources:
Disc. AE: Pruritic rash, Erythema edematous...
AEs leading to
discontinuation/dose reduction:
Pruritic rash (2 patients)
Erythema edematous (2 patients)
Vesicular eruption (2 patients)
Sources:
40 mg single, oral
Overdose
unhealthy, 80 years
n = 1
Health Status: unhealthy
Condition: angina pectoris
Age Group: 80 years
Sex: M
Population Size: 1
Sources:
Other AEs: Methemoglobinemia...
0.2 mg/h 1 times / day multiple, transdermal (starting)
Recommended
Dose: 0.2 mg/h, 1 times / day
Route: transdermal
Route: multiple
Dose: 0.2 mg/h, 1 times / day
Sources:
unhealthy, adult
n = 307
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 307
Sources:
Other AEs: Headache, Lightheadedness...
Other AEs:
Headache (63%)
Lightheadedness (6%)
Hypotension (4%)
Syncope (4%)
Sources:
1.5 mg 2 times / day multiple, rectal
Dose: 1.5 mg, 2 times / day
Route: rectal
Route: multiple
Dose: 1.5 mg, 2 times / day
Sources:
unhealthy, adult
Disc. AE: Hypotension...
AEs leading to
discontinuation/dose reduction:
Hypotension
Sources:
5 ug/kg 1 times / day single, subcutaneous
Dose: 5 ug/kg, 1 times / day
Route: subcutaneous
Route: single
Dose: 5 ug/kg, 1 times / day
Sources:
unhealthy, pediatric
n = 57
Health Status: unhealthy
Age Group: pediatric
Population Size: 57
Sources:
AEs

AEs

AESignificanceDosePopulation
Hypotension 4 patients
Disc. AE
1 ug/kg/min multiple, intravenous (starting)
Dose: 1 ug/kg/min
Route: intravenous
Route: multiple
Dose: 1 ug/kg/min
Sources:
pregnant, 26 years
n = 16
Health Status: pregnant
Condition: Preterm labor
Age Group: 26 years
Sex: F
Population Size: 16
Sources:
Headache severe, 1 patient
Disc. AE
8 ug/kg/min multiple, intravenous
Dose: 8 ug/kg/min
Route: intravenous
Route: multiple
Dose: 8 ug/kg/min
Sources:
pregnant, 26 years
n = 1
Health Status: pregnant
Condition: Preterm labor
Age Group: 26 years
Sex: F
Population Size: 1
Sources:
Nausea severe, 1 patient
Disc. AE
8 ug/kg/min multiple, intravenous
Dose: 8 ug/kg/min
Route: intravenous
Route: multiple
Dose: 8 ug/kg/min
Sources:
pregnant, 26 years
n = 1
Health Status: pregnant
Condition: Preterm labor
Age Group: 26 years
Sex: F
Population Size: 1
Sources:
Vomiting severe, 1 patient
Disc. AE
8 ug/kg/min multiple, intravenous
Dose: 8 ug/kg/min
Route: intravenous
Route: multiple
Dose: 8 ug/kg/min
Sources:
pregnant, 26 years
n = 1
Health Status: pregnant
Condition: Preterm labor
Age Group: 26 years
Sex: F
Population Size: 1
Sources:
Hemodynamic test abnormal 8 patients
Disc. AE
35 ug/kg/min single, intravenous
Dose: 35 ug/kg/min
Route: intravenous
Route: single
Dose: 35 ug/kg/min
Sources:
unhealthy, 50 years (range: 19 ± 74 years)
n = 105
Health Status: unhealthy
Age Group: 50 years (range: 19 ± 74 years)
Sex: M+F
Population Size: 105
Sources:
Erythema edematous 2 patients
Disc. AE
2 % 6 times / day multiple, topical
Dose: 2 %, 6 times / day
Route: topical
Route: multiple
Dose: 2 %, 6 times / day
Sources:
unhealthy, 57 - 71 years
n = 2
Health Status: unhealthy
Age Group: 57 - 71 years
Sex: M
Population Size: 2
Sources:
Pruritic rash 2 patients
Disc. AE
2 % 6 times / day multiple, topical
Dose: 2 %, 6 times / day
Route: topical
Route: multiple
Dose: 2 %, 6 times / day
Sources:
unhealthy, 57 - 71 years
n = 2
Health Status: unhealthy
Age Group: 57 - 71 years
Sex: M
Population Size: 2
Sources:
Vesicular eruption 2 patients
Disc. AE
2 % 6 times / day multiple, topical
Dose: 2 %, 6 times / day
Route: topical
Route: multiple
Dose: 2 %, 6 times / day
Sources:
unhealthy, 57 - 71 years
n = 2
Health Status: unhealthy
Age Group: 57 - 71 years
Sex: M
Population Size: 2
Sources:
Methemoglobinemia grade 5, 1 patient
40 mg single, oral
Overdose
unhealthy, 80 years
n = 1
Health Status: unhealthy
Condition: angina pectoris
Age Group: 80 years
Sex: M
Population Size: 1
Sources:
Hypotension 4%
0.2 mg/h 1 times / day multiple, transdermal (starting)
Recommended
Dose: 0.2 mg/h, 1 times / day
Route: transdermal
Route: multiple
Dose: 0.2 mg/h, 1 times / day
Sources:
unhealthy, adult
n = 307
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 307
Sources:
Syncope 4%
0.2 mg/h 1 times / day multiple, transdermal (starting)
Recommended
Dose: 0.2 mg/h, 1 times / day
Route: transdermal
Route: multiple
Dose: 0.2 mg/h, 1 times / day
Sources:
unhealthy, adult
n = 307
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 307
Sources:
Lightheadedness 6%
0.2 mg/h 1 times / day multiple, transdermal (starting)
Recommended
Dose: 0.2 mg/h, 1 times / day
Route: transdermal
Route: multiple
Dose: 0.2 mg/h, 1 times / day
Sources:
unhealthy, adult
n = 307
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 307
Sources:
Headache 63%
0.2 mg/h 1 times / day multiple, transdermal (starting)
Recommended
Dose: 0.2 mg/h, 1 times / day
Route: transdermal
Route: multiple
Dose: 0.2 mg/h, 1 times / day
Sources:
unhealthy, adult
n = 307
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 307
Sources:
Hypotension Disc. AE
1.5 mg 2 times / day multiple, rectal
Dose: 1.5 mg, 2 times / day
Route: rectal
Route: multiple
Dose: 1.5 mg, 2 times / day
Sources:
unhealthy, adult
PubMed

PubMed

TitleDatePubMed
Application site for nitroglycerin ointment.
1978 Dec
Coronary and myocardial metabolic effects of combined glyceryl trinitrate and propranolol administration. Observations in patients with and without coronary disease.
1978 Nov
Hypotension activates neuropeptide Y-containing neurons in the rat medulla oblongata.
1999
Acute normovolemic hemodilution and nitroglycerin-induced hypotension: comparative effects on tissue oxygenation and allogeneic blood transfusion requirement in total hip arthroplasty.
1999 Aug
Headaches in the treatment of anal fissure.
1999 Aug
Reproducibility of head-up tilt testing potentiated with sublingual nitroglycerin in patients with unexplained syncope.
1999 Aug 1
Acute myocardial infarction after the use of sildenafil.
1999 Aug 26
Continuous high-dose intracoronary nitroglycerin infusion in refractory coronary vasospasm.
1999 Dec
Involvement of ATP-sensitive potassium channels in a model of a delayed vascular hyporeactivity induced by lipopolysaccharide in rats.
1999 Jul
Spinal antinociceptive effect of epidural nonsteroidal antiinflammatory drugs on nitric oxide-induced hyperalgesia in rats.
1999 Jul
A comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure.
1999 Jul 8
Intracranial vessels in trigeminal transmitted pain: A PET study.
1999 May
Effects of nicardipine-, nitroglycerin-, and prostaglandin E1-induced hypotension on human cerebrovascular carbon dioxide reactivity during propofol-fentanyl anesthesia.
1999 Nov
Coronary spastic angina induced by anticholinesterase medication for myasthenia gravis--a case report.
2000 Dec
Paradoxical hypertensive response to nitroglycerin during cardiac catheterization.
2000 Dec
Effectiveness of modified release isosorbide mononitrate affected by incorrect use.
2000 Feb 19
Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability.
2000 Jan 7
Headache characteristics during the development of tolerance to nitrates: pathophysiological implications.
2000 Jun
Hypotensive interaction of sildenafil and nicorandil in rats through the cGMP pathway but not by K(ATP) channel activation.
2000 Nov
Echocardiographic assessment of coronary blood flow velocity during controlled hypotensive anesthesia with nitroglycerin.
2000 Oct
Nitroglycerin is preferable to diltiazem for prevention of coronary bypass conduit spasm.
2000 Sep
[Reactivity of cerebral vessels in patients with circulatory encephalopathy, arterial hypertension and cerebral hypoperfusion risk].
2001
Does nitric oxide play a role in the aetiology of pre-eclampsia?
2001 Apr
Topical diltiazem ointment in the treatment of chronic anal fissure.
2001 Apr
Nitric oxide modulation of blood vessel tone identified by arterial waveform analysis.
2001 Apr
S-Transnitrosylation of albumin in human plasma and blood in vitro and in vivo in the rat.
2001 Apr 7
Investigations into migraine pathogenesis: time course for effects of m-CPP, BW723C86 or glyceryl trinitrate on appearance of Fos-like immunoreactivity in rat trigeminal nucleus caudalis (TNC).
2001 Feb
Oxytocics reverse the tocolytic effect of glyceryl trinitrate on the human uterus.
2001 Feb
Acute myocardial infarction secondary to coronary vasospasm during withdrawal from industrial nitroglycerin exposure--a case report.
2001 Feb
NO donors inhibit Leishmania infantum cysteine proteinase activity.
2001 Feb 9
Enhanced 99Tc(m)-MIBI SPECT detection of hibernating myocardium following the use of sub-lingual nitroglycerine.
2001 Jan
Impaired vasodilator response to organic nitrates in isolated basilar arteries.
2001 Jan
Potentiation of sildenafil-induced hypotension is minimal with nitrates generating a radical intermediate.
2001 Jul
Transoesophageal acoustic quantification for evaluation of cardiac function during laparoscopic surgery.
2001 Jul
Pseudonormal diastolic filling unmasked with glyceryl trinitrate in patients with type 2 diabetes with poor metabolic control.
2001 Jul
Reduction of organic nitrates catalysed by xanthine oxidoreductase under anaerobic conditions.
2001 Jul 2
Long-term outcome of patients with ergonovine induced coronary constriction not associated with ischemic electrocardiographic changes.
2001 Jun
Nitric oxide in primary headaches.
2001 Jun
Ecstasy induced acute myocardial infarction.
2001 Jun
Augmentation of nitric oxide to treat detrusor-external sphincter dyssynergia in spinal cord injury.
2001 Jun 16
Technique for using video microscopy and indicator dilution for repeated measurements of cardiac output in small animals.
2001 Mar
Comparison of provocative tests for unexplained syncope: isoprenaline and glyceryl trinitrate for diagnosing vasovagal syncope.
2001 Mar
Urban-rural differences in the quality of care for medicare patients with acute myocardial infarction.
2001 Mar 12
Comparison of topically applied 0.2% glyceryl trinitrate ointment, incision and excision in the treatment of perianal thrombosis.
2001 May
Audit of topical glyceryl trinitrate for treatment of fissure-in-ano.
2001 May
Acute effects of vitamin C on platelet responsiveness to nitric oxide donors and endothelial function in patients with chronic heart failure.
2001 May
An update on nesiritide for treatment of decompensated heart failure.
2001 May
Effects of in vivo nitroglycerin treatment on activity and expression of the guanylyl cyclase and cGMP-dependent protein kinase and their downstream target vasodilator-stimulated phosphoprotein in aorta.
2001 May 1
Functional immunohistochemistry of neuropeptides and nitric oxide synthase in the nerve fibers of the supratentorial dura mater in an experimental migraine model.
2001 May 1
Patents

Patents

Sample Use Guides

Nitroglycerin in 5% Dextrose Injection is intended for intravenous administration using sterile equipment. It should be administered only via an infusion pump that can maintain a constant infusion rate. For treatment of acute anginal attack, one tablet of Nitrostat should be dissolved under the tongue or in the buccal pouch at the first sign of an acute anginal attack. The dose may be repeated approximately every 5 minutes, until relief is obtained. If the pain persists after a total of 3 tablets in a 15-minute period, or the pain is different than is typically experienced, prompt medical attention is recommended. Nitrostat may be used prophylactically 5 to 10 minutes prior to engaging in activities which might precipitate an acute attack.
Route of Administration: Other
Vasoactivity of nitroglycerin was measured using an ex vivo assay. Mice thoracic aortae were removed, cleaned, and cut into 3-mm rings. Rings were mounted on strain gauge transducers under 1 g of resting tension, and maintained at 37°C in Krebs solution, bubbled continuously with 20% O2/5% CO2/75% N2. Rings were allowed to equilibrate for 1 h before active tension was induced with prostaglandin F2α. Application of Nitroglycerine relieve the F2α-induced strain with IC50 of 10-7 M for wt mice, and 10-5 for mtALDH-/- mice.
Substance Class Chemical
Created
by admin
on Sat Jun 26 03:15:34 UTC 2021
Edited
by admin
on Sat Jun 26 03:15:34 UTC 2021
Record UNII
G59M7S0WS3
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NITROGLYCERIN
HSDB   MI   ORANGE BOOK   USP   VANDF  
Systematic Name English
NITRO-DUR
Brand Name English
GLYCERYL TRINITRATE [WHO-DD]
Common Name English
RECTIV
Brand Name English
NITRO IV
Brand Name English
GLYCERIN TRINITRATE
Systematic Name English
NITROGLYCERIN TABLETS [JAN]
Common Name English
DILUTED NITROGLYCERIN [USP-RS]
Common Name English
NITROGLYCERIN [ORANGE BOOK]
Common Name English
PROPANE-1,2,3-TRIYL TRINITRATE
Systematic Name English
MINITRAN
Brand Name English
GLONOINUM [HPUS]
Common Name English
TRINITRIN
Common Name English
NITROGLYCERIN [MI]
Common Name English
NITORA
Common Name English
NTG
Common Name English
TRINITRINE
Common Name English
NITROGLYCERIN [VANDF]
Common Name English
NITROMIST
Brand Name English
NITRONAL
Brand Name English
NITROL
Brand Name English
GONITRO
Common Name English
GLONOINUM
HPUS  
Common Name English
C01DA02
Code English
NITROLINGUAL
Brand Name English
TRIDIL
Brand Name English
GLYCERYL TRINITRATE
MART.   WHO-DD  
Systematic Name English
NITROSTAT
Brand Name English
DILUTED NITROGLYCERIN [USP MONOGRAPH]
Common Name English
GLYCERYL TRINITRATE [MART.]
Common Name English
TRANSDERM-NITRO
Brand Name English
TRINITROGLYCERIN
Systematic Name English
NITRO-BID
Brand Name English
1,2,3-PROPANETRIOL, TRINITRATE
Systematic Name English
NITROGLYCERIN [USP]
Common Name English
DILUTED NITROGLYCERIN
USP-RS  
Common Name English
GLYCEROL TRINITRATE
Systematic Name English
IMX-150
Common Name English
NITROGLYCERIN [HSDB]
Common Name English
1,2,3-PROPANETRIOL TRINITRATE
Systematic Name English
Classification Tree Code System Code
WHO-VATC QC05AE01
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
WHO-VATC QC01DA02
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
CFR 21 CFR 250.102
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
NDF-RT N0000007647
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
NDF-RT N0000007647
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
EU-Orphan Drug EU/3/15/1435
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
NCI_THESAURUS C29707
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
WHO-ATC C01DA52
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
WHO-ATC C05AE01
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
LIVERTOX 691
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
NDF-RT N0000007647
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
NDF-RT N0000009909
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 12.1
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
WHO-VATC QC01DA52
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
NDF-RT N0000007647
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
NDF-RT N0000175415
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
WHO-ATC C01DA20
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
WHO-ATC C01DA02
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
Code System Code Type Description
ECHA (EC/EINECS)
200-240-8
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
PRIMARY
FDA UNII
G59M7S0WS3
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
PRIMARY
PUBCHEM
4510
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
PRIMARY
DRUG CENTRAL
1952
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
PRIMARY
WIKIPEDIA
NITROGLYCERIN
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
PRIMARY
HSDB
30
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
PRIMARY
EVMPD
SUB11999MIG
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
PRIMARY
EPA CompTox
55-63-0
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
PRIMARY
NCI_THESAURUS
C29294
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
PRIMARY
IUPHAR
7053
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
PRIMARY
USP_CATALOG
1466506
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
PRIMARY USP-RS
ChEMBL
CHEMBL730
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
PRIMARY
MERCK INDEX
M7964
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
PRIMARY Merck Index
DRUG BANK
DB00727
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
PRIMARY
LACTMED
Nitroglycerin
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
PRIMARY
EVMPD
SUB13997MIG
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
PRIMARY
CAS
55-63-0
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
PRIMARY
RXCUI
4917
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
PRIMARY RxNorm
EVMPD
SUB90670
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
PRIMARY
CAS
9010-02-0
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
SUPERSEDED
MESH
D005996
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
PRIMARY
EVMPD
SUB96541
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
ALTERNATIVE
Related Record Type Details
BINDER->LIGAND
BINDING
Related Record Type Details
METABOLITE ACTIVE -> PRODRUG
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC